EMA Improves the Readability of Packaging Leaflets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Improves the Readability of Packaging Leaflets


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has updated the template for package leaflets to make the information easier for patients to understand. Leaflets will now include less rigid language and new sections that provide greater information about a drug’s benefits. There will also be more information about the medicine’s use in children to comply with the requirements of pediatric regulation.

The update addresses feedback received during a five-year period of user testing. Stakeholders, including patients, pharmaceutical companies, and national regulatory agencies also contributed their opinions. In addition, the update takes into account the EMA’s 2009 report on the expectations of patients, consumers, and healthcare professionals regarding benefit–risk information, which explains how patients are becoming increasingly involved in choosing their own treatments. In particular, the report called for clear information that is easy to read and understand.

The readability of packaging leaflets and labels is an issue that Pharmaceutical Technology Europe touched upon in May during an interview with Professor DK Theo Rynor. He explained that a number of commonly-used phrases, such as “Avoid alcoholic drink”, are often misunderstood by patients.

According to a statement from EMA, the update also includes changes to the templates for the summary of product characteristics, labeling and 'Annex II', the section of the product information covering the conditions imposed on marketing authorizations. The updated templates are available in all official EU languages, together with an implementation plan.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here